Cargando…

Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains

BACKGROUND: There continues to be debate about what constitutes a pragmatic trial and how it is distinguished from more traditional explanatory trials. The NIH Pragmatic Trials Collaborative Project, which includes five trials and a coordinating unit, has adopted the Pragmatic-Explanatory Continuum...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipman, Paula Darby, Loudon, Kirsty, Dluzak, Leanora, Moloney, Rachael, Messner, Donna, Stoney, Catherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681765/
https://www.ncbi.nlm.nih.gov/pubmed/29126437
http://dx.doi.org/10.1186/s13063-017-2267-y
_version_ 1783277975352901632
author Lipman, Paula Darby
Loudon, Kirsty
Dluzak, Leanora
Moloney, Rachael
Messner, Donna
Stoney, Catherine M.
author_facet Lipman, Paula Darby
Loudon, Kirsty
Dluzak, Leanora
Moloney, Rachael
Messner, Donna
Stoney, Catherine M.
author_sort Lipman, Paula Darby
collection PubMed
description BACKGROUND: There continues to be debate about what constitutes a pragmatic trial and how it is distinguished from more traditional explanatory trials. The NIH Pragmatic Trials Collaborative Project, which includes five trials and a coordinating unit, has adopted the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) instrument. The purpose of the study was to collect PRECIS-2 ratings at two points in time to assess whether the tool was sensitive to change in trial design, and to explore with investigators the rationale for rating shifts. METHODS: A mixed-methods design included sequential collection and analysis of quantitative data (PRECIS-2 ratings) and qualitative data. Ratings were collected at two annual, in-person project meetings, and subsequent interviews conducted with investigators were recorded, transcribed, and coded using NVivo 11 Pro for Windows. Rating shifts were coded as either (1) actual change (reflects a change in procedure or protocol), (2) primarily a rating shift reflecting rater variability, or (3) themes that reflect important concepts about the tool and/or pragmatic trial design. RESULTS: Based on PRECIS-2 ratings, each trial was highly pragmatic at the planning phase and remained so 1 year later in the early phases of trial implementation. Over half of the 45 paired ratings for the nine PRECIS-2 domains indicated a rating change from Time 1 to Time 2 (N = 24, 53%). Of the 24 rating changes, only three represented a true change in the design of the trial. Analysis of rationales for rating shifts identified critical themes associated with the tool or pragmatic trial design more generally. Each trial contributed one or more relevant comments, with Eligibility, Flexibility of Adherence, and Follow-up each accounting for more than one. CONCLUSIONS: PRECIS-2 has proved useful for “framing the conversation” about trial design among members of the Pragmatic Trials Collaborative Project. Our findings suggest that design elements assessed by the PRECIS-2 tool may represent mostly stable decisions. Overall, there has been a positive response to using PRECIS-2 to guide conversations around trial design, and the project’s focus on the use of the tool by this group of early adopters has provided valuable feedback to inform future trainings on the tool.
format Online
Article
Text
id pubmed-5681765
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56817652017-11-17 Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains Lipman, Paula Darby Loudon, Kirsty Dluzak, Leanora Moloney, Rachael Messner, Donna Stoney, Catherine M. Trials Research BACKGROUND: There continues to be debate about what constitutes a pragmatic trial and how it is distinguished from more traditional explanatory trials. The NIH Pragmatic Trials Collaborative Project, which includes five trials and a coordinating unit, has adopted the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) instrument. The purpose of the study was to collect PRECIS-2 ratings at two points in time to assess whether the tool was sensitive to change in trial design, and to explore with investigators the rationale for rating shifts. METHODS: A mixed-methods design included sequential collection and analysis of quantitative data (PRECIS-2 ratings) and qualitative data. Ratings were collected at two annual, in-person project meetings, and subsequent interviews conducted with investigators were recorded, transcribed, and coded using NVivo 11 Pro for Windows. Rating shifts were coded as either (1) actual change (reflects a change in procedure or protocol), (2) primarily a rating shift reflecting rater variability, or (3) themes that reflect important concepts about the tool and/or pragmatic trial design. RESULTS: Based on PRECIS-2 ratings, each trial was highly pragmatic at the planning phase and remained so 1 year later in the early phases of trial implementation. Over half of the 45 paired ratings for the nine PRECIS-2 domains indicated a rating change from Time 1 to Time 2 (N = 24, 53%). Of the 24 rating changes, only three represented a true change in the design of the trial. Analysis of rationales for rating shifts identified critical themes associated with the tool or pragmatic trial design more generally. Each trial contributed one or more relevant comments, with Eligibility, Flexibility of Adherence, and Follow-up each accounting for more than one. CONCLUSIONS: PRECIS-2 has proved useful for “framing the conversation” about trial design among members of the Pragmatic Trials Collaborative Project. Our findings suggest that design elements assessed by the PRECIS-2 tool may represent mostly stable decisions. Overall, there has been a positive response to using PRECIS-2 to guide conversations around trial design, and the project’s focus on the use of the tool by this group of early adopters has provided valuable feedback to inform future trainings on the tool. BioMed Central 2017-11-10 /pmc/articles/PMC5681765/ /pubmed/29126437 http://dx.doi.org/10.1186/s13063-017-2267-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lipman, Paula Darby
Loudon, Kirsty
Dluzak, Leanora
Moloney, Rachael
Messner, Donna
Stoney, Catherine M.
Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains
title Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains
title_full Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains
title_fullStr Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains
title_full_unstemmed Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains
title_short Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains
title_sort framing the conversation: use of precis-2 ratings to advance understanding of pragmatic trial design domains
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681765/
https://www.ncbi.nlm.nih.gov/pubmed/29126437
http://dx.doi.org/10.1186/s13063-017-2267-y
work_keys_str_mv AT lipmanpauladarby framingtheconversationuseofprecis2ratingstoadvanceunderstandingofpragmatictrialdesigndomains
AT loudonkirsty framingtheconversationuseofprecis2ratingstoadvanceunderstandingofpragmatictrialdesigndomains
AT dluzakleanora framingtheconversationuseofprecis2ratingstoadvanceunderstandingofpragmatictrialdesigndomains
AT moloneyrachael framingtheconversationuseofprecis2ratingstoadvanceunderstandingofpragmatictrialdesigndomains
AT messnerdonna framingtheconversationuseofprecis2ratingstoadvanceunderstandingofpragmatictrialdesigndomains
AT stoneycatherinem framingtheconversationuseofprecis2ratingstoadvanceunderstandingofpragmatictrialdesigndomains